Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07565389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Study acronym: AK112
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune checkpoint inhibitor and platinum-based chemotherapy.
Trial Details
NCT Number NCT07565389
Lead Sponsor National University Hospital, Singapore
Conditions
(from sponsor)		 Nasopharyngeal Carcinoma (NPC)
Related terms Nasopharyngeal Carcinoma
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov